A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Inclusion Criteria: * Provide written informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. * The patient is diagnosed as pheochromocytoma or paraganglioma which is unresectable with R0 surgery, or extensive and thus maybe requiring resection of important organs, or with very high surgical risk. * Laboratory requirements: * Absolute granulocyte count (AGC) greater than 1.5 x 109/L; * Platelet count greater than 80 x 109/L; * Hemoglobin greater than 90g/L; * Serum bilirubin less than 1.5 x upper limit of normal (ULN); * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 x ULN; * Serum creatinine less than 1.5 x ULN or creatinine clearance (CCr)≥60ml/min; * Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (50%). * Confirmed non-pregnancy and lactation. During the entire study period and within 6 months after the last administration, the subjects and their spouses are willing to use efficient contraceptive measures. Exclusion Criteria: * Patients who have previously used other anti-vascular targeted drugs, such as sunitinib, bevacizumab, endurance, etc. * Chemotherapy/systemic therapy, radiotherapy, immunotherapy or surgery within 4 weeks prior to kinase inhibitor therapy. * Patients with another primary malignancy within 5 years prior to starting study drug. * Those who have multiple factors that affect oral medications (such as ina…